Adrenoceptors, or adrenergic receptors, are the vital molecular transducers that bridge the sympathetic nervous system and dynamic physiological adaptation throughout the human body. By responding specifically to the endogenous catecholamines adrenaline and noradrenaline, these cell-surface proteins orchestrate everything from instantaneous fight-or-flight reactions to the delicate, long-term homeostatic regulation of vascular tone and metabolic flux. Understanding their structure, downstream cascades, and pharmacological profiles remains one of the cornerstones of modern physiology, neurobiology, and clinical therapeutics.
Adrenoceptor
1. Concise Definition
An adrenoceptor (frequently termed an adrenergic receptor) is a specialized cell-surface membrane protein belonging to the rhodopsin-like superfamily of G protein-coupled receptors (GPCRs). These receptors selectively bind and respond to endogenous catecholamines, primarily epinephrine (adrenaline) and norepinephrine (noradrenaline), as well as an extensive library of synthetic pharmacological ligands.
Functionally, adrenoceptors serve as the principal biochemical transducers through which sympathetic nervous activity and adrenal medullary secretions modulate cellular behaviors. Upon ligand binding, they undergo conformational transitions that trigger heterotrimeric G protein dissociation, initiating intracellular secondary messenger signaling cascades that regulate cardiovascular kinetics, smooth muscle contractility, bronchial tone, metabolic glycogenolysis, lipolysis, and central neurotransmission.
2. Etymology & Linguistic Origin
The term adrenoceptor is a portmanteau derived from adrenal and receptor. The prefix adreno- originates from the New Latin anatomical designation for the adrenal gland, constructed from the Latin preposition ad- (meaning “to” or “near”) and renes (meaning “kidneys”), referring directly to the physiological source where adrenaline was historically isolated. The suffix -ceptor derives from the Latin noun receptor (“a receiver” or “one who receives”), which stems from the verb recipere (composed of re-, “back,” and capere, “to take”).
Historically, the term was established in the mid-twentieth century as pharmacology transitioned from phenomenological tissue-bath experiments to molecular receptor theory. While early literature referred non-specifically to “adrenotropic receptors” or “sympathomimetic receptive substances,” standard international nomenclature (spearheaded by the International Union of Basic and Clinical Pharmacology, IUPHAR) solidified the term adrenoceptor to denote the target binding proteins distinct from the ligands themselves.
3. Pronunciation & Grammatical Form
Pronunciation: Phonetically transcribed as /əˌdriː.noʊ.sɛp.tər/ in American English and /əˌdriː.nəʊ.sɛp.tə/ in British English.
Grammatical Form: Countable noun. Plural: adrenoceptors. Derived adjectival forms include adrenoreceptive and adrenergic (the latter functioning interchangeably as an adjective to describe nerve fibers, drugs, or receptor mechanisms associated with epinephrine and norepinephrine). Syntactically, it frequently appears as an attributive noun, as in adrenoceptor antagonist, adrenoceptor kinase, or adrenoceptor density.
4. Detailed Conceptual Explanation
At their structural core, adrenoceptors consist of a single polypeptide chain configured into seven transmembrane-spanning alpha-helices (TM1 through TM7), an extracellular amino-terminus (N-terminus) that often displays functional glycosylation sites, three extracellular loops (ECL1–ECL3), three intracellular loops (ICL1–ICL3), and an intracellular carboxyl-terminus (C-terminus). The third intracellular loop and the carboxyl tail possess critical regulatory motifs, including phosphorylation sites targeted by G protein-coupled receptor kinases (GRKs) and second-messenger-activated kinases like protein kinase A (PKA).
The fundamental mechanism of adrenoceptor activation rests upon structural dynamics. In the resting or unliganded state, internal hydrogen-bonding networks and ionic locks—such as the highly conserved DRY (Asp-Arg-Tyr) motif in TM3 and the NPxxY motif in TM7—stabilize the receptor in a low-activity basal equilibrium. When an agonist (such as norepinephrine) enters the orthosteric binding pocket formed by residues within TM3, TM5, TM6, and TM7, critical ionic and hydrophobic interactions occur, notably between the protonated amine of the catecholamine and an invariant aspartate residue in TM3, alongside hydrogen bonding with serine residues in TM5. This binding alters the conformational free-energy landscape, prompting an outward displacement of TM6 and opening a cytoplasmic cavity that accommodates the alpha-subunit of a heterotrimeric G protein complex.
The scope of adrenoceptor signaling diverges substantially based on the specific subclass involved. Adrenoceptors are broadly divided into three major structural and functional families: alpha-1 (α₁), alpha-2 (α₂), and beta (β) adrenoceptors, which encompass a total of nine distinct gene products (α₁A, α₁B, α₁D; α₂A, α₂B, α₂C; β₁, β₂, and β₃). Each family couples preferentially to distinctive G protein alpha-subunits:
- α₁-Adrenoceptors: Couple primarily to Gq/11 proteins. Activation stimulates phospholipase C-beta (PLCβ), which hydrolyzes membrane phosphatidylinositol 4,5-bisphosphate (PIP₂) into inositol 1,4,5-trisphosphate (IP₃) and diacylglycerol (DAG). IP₃ mobilizes intracellular calcium (Ca²⁺) from the sarcoplasmic/endoplasmic reticulum, whereas DAG activates protein kinase C (PKC), culminating in smooth muscle contraction and cellular hypertrophy.
- α₂-Adrenoceptors: Couple primarily to Gi/o proteins. Their activation inhibits adenylyl cyclase, lowering intracellular cyclic adenosine monophosphate (cAMP) levels, while their associated Gβγ subunits directly activate G protein-coupled inwardly rectifying potassium (GIRK) channels and suppress voltage-gated N- and P/Q-type Ca²⁺ channels. This leads to membrane hyperpolarization and attenuation of neurotransmitter exocytosis.
- β-Adrenoceptors: Couple predominantly to Gs proteins. Activation stimulates adenylyl cyclase activity, increasing intracellular cAMP synthesis and triggering PKA-mediated phosphorylation of numerous cellular substrates, such as phospholamban, troponin I, and L-type calcium channels in the myocardium, leading to positive inotropy, chronotropy, and dromotropy, as well as smooth muscle relaxation in bronchial and vascular beds.
The boundary conditions of adrenoceptor activity are strictly regulated by desensitization and internalization machinery. Persistent agonist occupancy recruits GRKs, which selectively phosphorylate the intracellular domains of the receptor. This phosphorylation increases affinity for beta-arrestins (arrestin-2 and arrestin-3). Beta-arrestin binding physically sterically hinders further G protein interaction (homologous desensitization) and targets the receptor to clathrin-coated pits for endocytosis, routing the receptor toward either endosomal dephosphorylation and recycling or lysosomal degradation.
5. Historical Development
The conceptual genesis of adrenoceptors traces back to the late nineteenth and early twentieth centuries. In 1895, George Oliver and Edward Albert Schäfer observed dramatic increases in arterial blood pressure upon injecting adrenal gland extracts into animals. Shortly after adrenaline was isolated and synthesized by Jokichi Takamine and Thomas Bell Aldrich in 1901, John Newport Langley (1905) proposed the revolutionary concept of a “receptive substance” residing on effector cells that mediates drug-induced physiological responses.
In 1906, Sir Henry Hallett Dale made the pivotal observation that certain ergot alkaloids could selectively abolish the pressor (vasoconstrictive) responses of adrenaline without extinguishing its depressor (vasodilatory and cardiac accelerative) actions. This functional dichotomy baffled pharmacologists for four decades until Raymond P. Ahlquist published his historic 1948 paper in the American Journal of Physiology. Ahlquist investigated the rank-order potency of six catecholamines across diverse physiological tissues and proposed that there were two distinct populations of receptors, which he designated as alpha (mediating mainly excitatory responses, except for intestinal inhibition) and beta (mediating predominantly inhibitory actions, except for cardiac excitation).
The validity of Ahlquist’s dual receptor hypothesis was firmly established when James Black and colleagues developed the first clinically effective beta-adrenoceptor antagonist, pronethalol, followed by propranolol in 1964, an achievement for which Black received the 1988 Nobel Prize in Physiology or Medicine. In 1967, A. M. Lands and his associates further subdivided the beta-adrenoceptors into β₁ (cardiac stimulation and lipolysis) and β₂ (bronchodilation and vasodilation) based on the selective potency profiles of various catecholamine derivatives.
During the 1970s and 1980s, the advent of radioligand binding assays spearheaded by Robert J. Lefkowitz and colleagues enabled the physical isolation and molecular cloning of adrenoceptor cDNAs, definitively demonstrating that they belonged to the seven-transmembrane G protein-coupled receptor superfamily. Lefkowitz and Brian Kobilka were jointly awarded the 2012 Nobel Prize in Chemistry for their structural and molecular characterization of GPCRs, highlighted by high-resolution crystallographic depictions of the human β₂-adrenoceptor in both inactive and active G protein-complexed states.
6. Theoretical Foundations
The functional understanding of adrenoceptors is anchored in Classical Receptor Theory and its modern evolution into Allosteric and Biased Signaling Models. Historically, A. J. Clark’s Occupancy Theory postulated that physiological response magnitude was directly proportional to the fraction of adrenoceptors occupied by a ligand. This foundational framework was subsequently refined by E. J. Ariëns, who introduced the concept of intrinsic activity, and Stephenson, who formulated efficacy and demonstrated the existence of “spare receptors” (receptor reserve), where maximal tissue response could occur with only a tiny fraction of adrenoceptors bound.
As biophysical and structural methodologies advanced, the rigid two-state model (active versus inactive) was superseded by the Multistate Allosteric Model and the Extended Ternary Complex Model. According to these frameworks, adrenoceptors exist within a dynamic ensemble of conformational states. Ligands act not merely as simple on/off switches, but rather as allosteric modulators that shift conformational equilibria toward distinct functional states.
This paradigm led directly to the concept of functional selectivity or biased agonism. In traditional pharmacology, an adrenoceptor agonist was presumed to activate all downstream effector pathways uniformly. Contemporary biophysical research demonstrates that specific synthetic ligands can stabilize distinct adrenoceptor conformations, thereby preferentially engaging G protein signaling over beta-arrestin recruitment, or vice versa. Biased agonism at adrenoceptors represents a revolutionary framework in modern drug development, permitting the theoretical design of therapeutic molecules that promote therapeutically beneficial signaling cascades while avoiding conformations responsible for side effects and receptor down-regulation.
7. Key Components, Types & Dimensions
The adrenoceptor family encompasses nine officially recognized mammalian subtypes, categorized into three principal clades based on structural homology, pharmacological profiles, and signaling coupling:
- Alpha-1A Adrenoceptor (α₁A): Predominantly localized in vascular smooth muscle, human prostate tissue, and the heart. Mediates smooth muscle contraction, peripheral vascular resistance, and prostatic smooth muscle tone via Gq/11, PLCβ, IP₃, and intracellular Ca²⁺ release.
- Alpha-1B Adrenoceptor (α₁B): Widely expressed in the cerebral cortex, kidneys, and spleen. Plays critical roles in regulating arterial blood pressure and promoting cellular growth and hypertrophy pathways in vascular smooth muscle.
- Alpha-1D Adrenoceptor (α₁D): High expression in the aorta, coronary arteries, and urinary bladder. Involved in the maintenance of basal vascular tone and lower urinary tract contractions.
- Alpha-2A Adrenoceptor (α₂A): Highly concentrated presynaptically in sympathetic nerve terminals and the central nervous system (e.g., locus coeruleus), as well as in pancreatic islet beta-cells and blood platelets. Serves as the principal autoreceptor mediating negative feedback on norepinephrine release, suppresses central sympathetic outflow, and inhibits insulin secretion via Gi/o.
- Alpha-2B Adrenoceptor (α₂B): Prominent in neonatal brain tissue and peripheral vascular smooth muscle. Mediates rapid, transient vasoconstriction during systemic administration of non-selective α₂ agonists.
- Alpha-2C Adrenoceptor (α₂C): Enriched in the basal ganglia, hippocampus, and adrenal medulla. Modulates neurobehavioral stress responses, cognitive processing, and adrenal catecholamine secretion.
- Beta-1 Adrenoceptor (β₁): Primarily expressed in cardiac myocytes, sinoatrial and atrioventricular nodes, and juxtaglomerular cells of the kidney. Couples to Gs to augment cardiac chronotropy (rate), inotropy (contractility), and dromotropy (conduction velocity), as well as to drive renin release into the circulation.
- Beta-2 Adrenoceptor (β₂): Widely distributed in bronchial smooth muscle, gastrointestinal tract, skeletal muscle vasculature, liver, and mast cells. Couples predominantly to Gs (with potential switching to Gi), causing smooth muscle relaxation, bronchial dilation, glycogenolysis, and stabilization of mast cell degranulation.
- Beta-3 Adrenoceptor (β₃): Expressed abundantly in white and brown adipose tissue, the urinary bladder detrusor muscle, and the gallbladder. Stimulates lipolysis and thermogenesis via Gs, and mediates detrusor smooth muscle relaxation during the bladder filling phase.
8. Examples & Illustrative Cases
The clinical manifestations of adrenoceptor pharmacology are best illustrated through real-world medical and physiological scenarios:
Case 1: Systemic Anaphylaxis and Epinephrine Administration. In a severe systemic anaphylactic reaction, widespread degranulation of mast cells releases histamine, leukotrienes, and cytokines, inducing severe bronchospasm and profound distributive shock. The emergency administration of epinephrine activates multiple adrenoceptor subtypes simultaneously: stimulation of β₂-adrenoceptors on bronchial smooth muscle causes rapid bronchodilation and inhibits further mediator release; stimulation of α₁-adrenoceptors on peripheral resistance vessels induces vasoconstriction, reversing hypotension and laryngeal edema; and activation of cardiac β₁-adrenoceptors enhances stroke volume and heart rate to restore systemic perfusion.
Case 2: Pheochromocytoma and Receptor Dynamics. In patients with pheochromocytoma—a rare neuroendocrine tumor of chromaffin tissue that hypersecretes catecholamines—patients present with episodic or sustained hypertensive crises, diaphoresis, and tachycardia. Excessive stimulation of vascular α₁-adrenoceptors precipitates profound vasoconstriction, while β₁-adrenoceptor hyperstimulation drives palpitations and arrhythmias. Surgical resection requires preoperative pharmacological preparation with irreversible alpha-blockers (e.g., phenoxybenzamine) to relieve vasoconstriction prior to initiating beta-blocker therapy; administering a beta-blocker alone would eliminate β₂-mediated vasodilation, resulting in unopposed α₁-mediated vasoconstriction and fatal hypertensive encephalopathy.
Case 3: Lower Urinary Tract Symptoms and Selective α₁-Antagonism. In men with benign prostatic hyperplasia (BPH), urinary outflow obstruction arises partly from mechanical tissue enlargement and partly from α₁A-mediated tone in the prostate stroma and bladder neck. Therapeutic administration of tamsulosin, an antagonist with preferential affinity for α₁A over α₁B receptors, relieves urethral resistance and improves urinary flow with a minimal incidence of vascular α₁B-mediated orthostatic hypotension.
9. Measurement & Assessment
Evaluating adrenoceptor expression, functionality, and ligand pharmacology involves an integrated suite of biochemical, biophysical, and clinical methodologies:
- Radioligand Binding Assays: The classical quantitative gold standard. By incubating membrane preparations with high-affinity radiolabeled ligands (such as [³H]-dihydroalprenolol for beta receptors or [³H]-prazosin for α₁ receptors), researchers determine receptor density (Bmax) and equilibrium dissociation constants (Kd) via saturation and competitive binding analyses.
- Bioluminescence and Fluorescence Resonance Energy Transfer (BRET/FRET): Real-time biophysical assays in living cells. These platforms monitor conformational transitions, G-protein coupling kinetics, and beta-arrestin recruitment by tagging adrenoceptors and transducer proteins with complementary fluorophores or luciferases.
- Cryo-Electron Microscopy (Cryo-EM) and X-ray Crystallography: Advanced structural imaging techniques that provide atomic-resolution structures of adrenoceptors in complexes with agonists, antagonists, G proteins, and arrestins, elucidating exact molecular docking geometries.
- Physiological and Autonomic Function Testing: In humans, adrenoceptor sensitivity is clinically evaluated through cardiovascular hemodynamic monitoring. Tests include assessing heart rate and blood pressure responses to graded infusions of selective agonists (e.g., isoproterenol for β-sensitivity or phenylephrine for α-sensitivity), the cold pressor test, tilt-table testing, and microneurographic recording of muscle sympathetic nerve activity (MSNA).
10. Applications & Practical Significance
Adrenoceptors serve as the primary pharmacological targets across numerous medical specialties, spanning cardiology, pulmonology, neurology, and psychiatry:
Cardiovascular Medicine: Beta-adrenoceptor antagonists (beta-blockers such as metoprolol, carvedilol, and bisoprolol) represent fundamental therapies for chronic heart failure, coronary artery disease, and cardiac arrhythmias. By shielding the heart from chronic sympathetic hyperactivation, they reduce myocardial oxygen demand, suppress arrhythmogenic foci, and reverse adverse ventricular remodeling. Meanwhile, selective α₁-blockers (doxazosin) manage systemic hypertension, and central α₂-agonists (clonidine, methyldopa) reduce peripheral resistance by diminishing sympathetic outflow from the brainstem.
Pulmonology: Short-acting beta-2 agonists (SABAs like albuterol) and long-acting beta-2 agonists (LABAs like salmeterol and formoterol) are foundational treatments for asthma and chronic obstructive pulmonary disease (COPD). Their binding to bronchial β₂-adrenoceptors activates adenylyl cyclase, lowers intracellular calcium, and induces rapid, long-lasting airway smooth muscle relaxation.
Urology and Anesthesiology: In addition to α₁A-antagonists for benign prostatic hyperplasia, the selective β₃-adrenoceptor agonist mirabegron is utilized to relax the detrusor muscle in overactive bladder syndrome without the dry-mouth side effects of anticholinergic drugs. In critical care and anesthesiology, α₂-adrenoceptor agonists (dexmedetomidine) provide sedation and analgesia without respiratory depression, while potent synthetic alpha- and beta-agonists (norepinephrine, epinephrine, phenylephrine, dobutamine) serve as critical inotropes and vasopressors during septic, cardiogenic, and neurogenic shock.
Psychiatry and Cognitive Neuroscience: Noradrenergic transmission via central α₂- and β-adrenoceptors modulates arousal, vigil, attention, and memory consolidation. The α₁-antagonist prazosin crosses the blood-brain barrier and is clinically utilized to alleviate severe trauma-related nightmares and sleep disturbances in Post-Traumatic Stress Disorder (PTSD) by dampening central hyperadrenergic signaling.
11. Research & Empirical Evidence
Extensive clinical and laboratory investigations have solidified our understanding of adrenoceptor behavior under physiological and pathological stress. In chronic heart failure, sustained sympathetic elevation leads to a profound (~50%) selective down-regulation and functional uncoupling of myocardial β₁-adrenoceptors, primarily mediated by up-regulated G-protein receptor kinase 2 (GRK2). Clinical trials, such as the landmark MERIT-HF (Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure) and CIBIS-II (Cardiac Insufficiency Bisoprolol Study II), empirically demonstrated that chronically blocking these receptors with beta-blockers significantly reduces all-cause mortality and sudden cardiac death, confirming that sympathetic hyperactivity is cardiotoxic rather than compensatory over extended durations.
In human genetics, widespread polymorphisms within adrenoceptor-encoding genes (e.g., ADRB1, ADRB2, ADRA2A) have been uncovered, explaining individual variation in drug response and disease susceptibility. A well-characterized variation in the ADRB2 gene (Arg16Gly) alters the susceptibility of the receptor to agonist-promoted down-regulation. Patients homozygous for Gly16 experience greater receptor desensitization during prolonged use of β₂-agonists in asthma regimens, highlighting the importance of pharmacogenomics in tailoring adrenergic therapeutic strategies.
12. Cultural & Cross-Cultural Considerations
While the biological structure of adrenoceptors is conserved across our species, substantial variations in therapeutic response and disease presentations occur across different ancestral and cross-cultural cohorts due to allele frequencies and environmental interactions. For instance, the Arg389Gly polymorphism of the ADRB1 gene exhibits pronounced frequency disparities between populations of African, European, and East Asian ancestry. Individuals carrying the Arg389 allele display substantially greater hemodynamic responsiveness and survival benefits when treated with beta-blockers compared to those with the Gly389 variant.
Epidemiological and clinical trial observations, such as those noted in the African American Heart Failure Trial (A-HeFT), demonstrated that therapeutic regimens targeting vascular and neurohumoral mechanisms must account for geographic and ethnic differences in baseline renin-angiotensin-aldosterone and sympathetic tone. Furthermore, sociodemographic factors, dietary electrolyte intake, access to health services, and varying cultural expressions of chronic psychosocial stress profoundly influence basal sympathetic tone, which directly modifies the regulatory turnover and baseline sensitivity of adrenoceptor networks across diverse global populations.
13. Criticisms, Debates & Limitations
Despite more than a century of intensive study, adrenoceptor pharmacology presents several unresolved controversies, therapeutic limitations, and scientific debates:
- Receptor Selectivity vs. Non-Target Toxicity: Classical small-molecule agonists and antagonists frequently exhibit relative rather than absolute selectivity. High clinical doses of selective β₂-agonists can provoke β₁-mediated tachycardia and tremor, while non-selective beta-blockers can cross-react with β₂-receptors to trigger life-threatening bronchospasm in patients with reactive airway disease.
- Beta-Blocker Withdrawal Phenomenon: Abrupt cessation of chronic beta-adrenoceptor antagonist therapy often precipitates a rebound hypertensive or tachycardic crisis. This occurs because the cells respond to chronic antagonist exposure by up-regulating adrenoceptor surface density, creating a hyper-sensitized state that exaggerates the response to normal levels of endogenous catecholamines upon drug removal.
- The Paradigm of Biased Agonism: While biased signaling at GPCRs offers the promise of pathway-specific therapeutics, determining whether physiological responses in cell-based screening assays translate accurately to whole-organ clinical models remains hotly debated, as cell-type-specific receptor reserves can obscure true signaling bias.
- Subtype Redundancy and Knockout Compensation: Rodent knockout models for individual adrenoceptor subtypes frequently exhibit subtle or ambiguous phenotypes, pointing to functional compensation by other adrenoceptors or neurohumoral axes that complicates precise mechanistic isolation.
14. Related Terms & Distinctions
To avoid conceptual confusion, adrenoceptors must be distinguished from several related molecular and biological entities:
- Dopamine Receptors (D₁–D₅): Also belonging to the GPCR superfamily and responding to catecholamines, dopamine receptors share high structural homology with adrenoceptors but exhibit distinct ligand-binding pockets fine-tuned for dopamine over norepinephrine and epinephrine.
- Muscarinic Acetylcholine Receptors: GPCRs that respond to acetylcholine rather than catecholamines. They typically operate in functional opposition to adrenoceptors within dual-innervated autonomic organs (e.g., M₂ receptors slow heart rate, opposing β₁ acceleration).
- Adrenomedullin Receptors: Peptide-activated GPCR heterodimers (comprising calcitonin receptor-like receptor and receptor activity-modifying proteins) that bind adrenomedullin. They do not respond to catecholamines despite the common “adreno-” prefix.
- Trace Amine-Associated Receptors (TAARs): Intracellular GPCRs that recognize endogenous trace amines (e.g., tyramine, octopamine, phenylethylamine) and can modulate adrenergic tone, yet are phylogenetically and functionally distinct from classical adrenoceptors.
15. Summary / Key Takeaways
Adrenoceptors serve as the fundamental molecular transducers of the sympathetic nervous system and adrenal medulla, enabling systemic physiological adaptation to physical exertion, environmental stressors, and changes in metabolic demand. Classified into alpha-1 (Gq-coupled), alpha-2 (Gi-coupled), and beta (Gs-coupled) subtypes, they regulate a diverse array of responses including vasoconstriction, smooth muscle relaxation, cardiac output acceleration, neurotransmitter feedback inhibition, and metabolic substrate mobilization. Spanning historical breakthroughs from Ahlquist to modern structural determination via cryo-EM, adrenoceptors continue to provide indispensable therapeutic targets for treating heart failure, hypertension, asthma, and shock. Current and future developments focus on biased agonism, allosteric modulation, and pharmacogenomics to enhance clinical precision and reduce off-target liabilities.
References
- Ahlquist, R. P. (1948). A study of the adrenotropic receptors. American Journal of Physiology, 153(3), 586–600. https://doi.org/10.1152/ajplegacy.1948.153.3.586
- Bylund, D. B., Eikenberg, D. C., Hieble, J. P., Langer, S. Z., Lefkowitz, R. J., Minneman, K. P., Molinoff, P. B., Ruffolo, R. R., & Trendelenburg, U. (1994). International Union of Pharmacology nomenclature of adrenoceptors. Pharmacological Reviews, 46(2), 121–136. https://pharmrev.aspetjournals.org/content/46/2/121
- Lefkowitz, R. J. (2013). A brief history of G-protein coupled receptors (Nobel Lecture). Angewandte Chemie International Edition, 52(25), 6366–6378. https://doi.org/10.1002/anie.201301924
- Rasmussen, S. G., Choi, H. J., Rosenbaum, D. M., Kobilka, T. S., Thian, F. S., Edwards, P. C., Burghammer, M., Ratnala, V. R., Sanishvili, R., Fischetti, R. F., Schertler, G. F., Weis, W. I., & Kobilka, B. K. (2007). Crystal structure of the human β2 adrenergic G-protein-coupled receptor. Nature, 450(7168), 383–387. https://doi.org/10.1038/nature06325
- Strosberg, A. D. (1993). Structure, function, and regulation of adrenergic receptors. Protein Science, 2(8), 1198–1209. https://doi.org/10.1002/pro.5560020802